Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 26, 2026, Efrat L. Greenstein Brayer, an independent member of the Board of Directors (the “Board”) of SKYX Platforms Corp. (the “Company”), passed away. Ms.…
Filed Oct 1, 2026Accepted Oct 1, 2026, 5:15 PM EDTCIK 1598981Accession 0001493152-26-045379
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.01Item 3.01 - Notice of Delisting
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
September 26, 2026, Efrat L. Greenstein Brayer, an independent member of the Board of Directors (the “Board”) of SKYX Platforms
Corp. (the “Company”), passed away. Ms. Greenstein Brayer was a member of the audit committee and the compensation committee
and the chair of the nominating and corporate governance committee of the Board. Ms. Greenstein Brayer was a highly respected member
of the Board, and the Board and management are deeply saddened by her passing.
On
September 28, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) that, due to Ms. Greenstein Brayer’s
passing, the Company was no longer in compliance with Nasdaq Listing Rule 5605(b)(1), requiring that a majority of the Company’s
Board consist of independent directors, and Nasdaq Listing Rule 5605(c)(2)(A), requiring that the Company’s audit committee consist
of at least three members.
On
September 30, 2026, the Company received a letter from Nasdaq notifying the Company of the available cure period. Pursuant to Nasdaq
Listing Rule 5605(b)(1)(A) and 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rules
5605(b)(1) and 5605(c)(2)(A), which cure period will expire upon the earlier of the Company’s next annual meeting of stockholders
or September 26, 2027; provided, however, that if the next annual meeting of stockholders is held before March 25, 2027, then the Company
must evidence compliance no later than March 25, 2027.
The
Company intends to take sufficient actions to regain compliance with the foregoing Nasdaq governance requirements on or before the expiration
of the applicable cure periods provided in the Nasdaq Listing Rules. However, there can be no assurance that Company will be able to
regain compliance with the applicable Nasdaq Listing Rules set forth above within the required cure period.
The
foregoing has no immediate effect on the Company’s Nasdaq listing, subject to compliance with the listing rules.